Proposed Collection; Comment Request; Simulations for Drug Related Science Education, 52053-52054 [E8-20778]
Download as PDF
<![CDATA[
52053
Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices
To increase awareness of the
seriousness of diabetes, its risk factors,
and strategies for preventing diabetes
and its complications among people at
risk for diabetes; (2) to improve
understanding about diabetes and its
control and to promote better selfmanagement behaviors among people
with diabetes; (3) to improve health care
providers’ understanding of diabetes
and its control and to promote an
integrated approach to care; (4) to
promote health care policies that
improve the quality of and access to
diabetes care.
Multiple strategies have been devised
to address the NDEP objectives. These
have been described in the NDEP
Strategic Plan and include: (1) Creating
partnerships with other organizations
concerned about diabetes; (2)
developing and implementing
awareness and education activities with
special emphasis on reaching the racial
and ethnic populations
disproportionately affected by diabetes;
(3) identifying, developing, and
disseminating educational tools and
resources for the program’s diverse
audiences; (4) promoting policies and
activities to improve the quality of and
access to diabetes care.
The NDEP evaluation will document
the extent to which the NDEP program
has been implemented, and how
successful it has been in meeting
program objectives. The evaluation
relies heavily on data gathered from
existing national surveys such as
National Health and Nutrition
Examination Survey (NHANES), the
National Health Interview Survey
(NHIS), the Behavioral Risk Factor
Surveillance System (BRFSS), among
others for this information. This generic
clearance request is for the collection of
additional primary data from NDEP
target audiences on some key process
and impact measures that are necessary
to effectively evaluate the program.
Approval is requested for a survey of
audiences targeted by the National
Diabetes Education Program including
people at risk for diabetes, people with
diabetes and their families and the
public.
Frequency of Response: On occasion.
Affected Public: Individuals or
households. Type of Respondents:
Adults. The annual reporting burden is
as follows: Estimated Number of
Respondents: 3759, Estimated Number
of Responses per Respondent: 1;
Average Burden Hours per Response:
.153; and Estimated Total Annual
Burden Hours Requested: 575. There are
no Capital, Operating or Maintenance
Costs to report.
ESTIMATES OF HOUR BURDEN
Average
time per
response
Number of
respondents
Frequency
of response
Screening interview with ineligible persons .....................................................................
Eligible respondents ........................................................................................................
1659
2100
1
1
.03
.25
50
525
Totals ........................................................................................................................
3759
....................
....................
575
Type of respondents
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
mstockstill on PROD1PC66 with NOTICES
FOR FURTHER INFORMATION CONTACT:
To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact Joanne Gallivan,
M.S., R.D., Director, National Diabetes
Education Program, NIDDK, NIH,
Building 31, Room 9A06, 31 Center
Drive, Bethesda, MD 20892, call the
non-toll-free number 301–494–6110 or
VerDate Aug<31>2005
17:59 Sep 05, 2008
Jkt 214001
e-mail your request, including your
address to: Joanne_Gallivan@nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: June 9, 2008.
Elizabeth E. Greene,
Executive Officer, NIDDK, National Institutes
of Health.
Editorial Note: This document was
received in the Office of the Federal Register
on September 3, 2008.
[FR Doc. E8–20636 Filed 9–5–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Simulations for Drug Related
Science Education
SUMMARY: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institute on Drug Abuse (NIDA), the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Total hour
burden
and approval of the information
collection listed below. This proposed
information collection was previously
published in the Federal Register on
June 26, 2008, (Vol. 73 No. 124, page
36337) and allowed 60-days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Institutes of
Health may not conduct or sponsor, and
the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after September 24,
2008, unless it displays a currently valid
OMB control number.
Proposed Collection: Title:
Simulations for Drug Related Science
Education. Type of Information
Collection Request: NEW. Need and Use
of Information Collection: This is a
request for a one-time clearance to
evaluate an interactive multimedia
module developed by ArchieMD. This
evaluation seeks to determine whether
the multimedia module Archie MD: The
Science of Drugs (1) Increases students’
knowledge in brain and heart biology
and the effects drugs have on the body
(2) Increases positive attitudes towards
science education for high school
students (3) Reinforce or instill negative
E:\FR\FM\08SEN1.SGM
08SEN1
52054
Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices
attitudes towards substance abuse. In
order to test the effectiveness of the
interactive multimedia module, data
will be collected in the form of pre and
post test surveys from 10th and 11th
grade high school students utilizing the
developed module. The findings will
provide valuable information regarding
information pertaining to the use of
interactive multimedia educational
modules in high school science
classrooms and their ability to increase
knowledge and change attitudes and
perceptions.
Frequency of Response: 4. Affected
Public: High school students engaged
with the ArchieMD: The Science of
Drugs program. Type of Respondent:
Participants will include high school
students enrolled in the tenth and
eleventh grade. Estimated Total Annual
Number of Respondents: 360. Estimated
Number of
respondents
Type of respondents
Number of Responses per Respondent:
4. Average Burden Hours per Response:
One high school period lasting 50
minutes. Estimated Total Annual
Burden Hours Requested: 1199.95.
There are no Capital Costs to report.
There are no Operating or Maintenance
Costs to report. The estimated
annualized burden is summarized
below.
Average
burden hours
per response
Frequency
of response
Estimated total
burden hours
requested
Participants—High School Students ................................................................
360
4
.8333
1199.95
Total ..........................................................................................................
360
4
.8333
1199.95
mstockstill on PROD1PC66 with NOTICES
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (3) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plans, please
contact Dr. Cathrine Sasek, Coordinator,
Science Education Program, Office of
Science Policy and Communications,
National Institute on Drug Abuse, 6001
Executive Blvd, Room 5237, Bethesda,
MD 20892, or call non-toll-free number
(301) 443–6071; fax (301) 443–6277; or
by e-mail to csasek@nida.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60-days of the date of
this publication.
Dated: August 25, 2008.
Mary Affeldt,
Associate Director for Management, National
Institute on Drug Abuse, National Institutes
of Health.
[FR Doc. E8–20778 Filed 9–5–08; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
17:59 Sep 05, 2008
Jkt 214001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Over-Expression and Mutation of a
Tyrosine Kinase Receptor FGFR4 in
Tumors
Description of Technology:
Rhabdomyosarcoma (RMS) is the most
common type of pediatric soft tissue
sarcoma. Most children (>70%) with the
disease die at higher stage (metastatic
disease).
Researchers at NIH have identified
mutations in fibroblast growth factor
receptor 4 (FGFR4) that are associated
with RMS tumors. It is proposed that
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
individuals with FGFR4 mutations may
have an increased risk for tumor
metastasis. The identified FGFR4
variants can be used to identify
individuals who may benefit most from
treatment with an FGFR4 inhibitor as an
adjuvant to standard anticancer
therapeutics to decrease the risk of
tumor metastasis.
Available for licensing are methods
for identifying candidates for treatment
with an inhibitor of FGFR4 by
determining the presence of at least one
FGFR4 variant, kits for identifying said
candidates, and methods for identifying
compounds that induce tumor cell
death or that inhibit tumor growth or
metastasis.
Applications:
• Potential new method for treatment
of Rhabdomyosarcomas (RMS).
• Potential new method to prepare
kits to diagnose activating mutations in
FGFR4.
• These mutations can be used in
laboratory settings to screen thousands
of compounds for more specific FGFR4
gene inhibitors.
• FGFR4 is also a potential target for
lung and breast cancer.
• FGFR4 monoclonal can be
developed to target RMS tumors.
Market:
• In the United States, approximately
12,000 new cases of cancer are
diagnosed in children each year.
Childhood cancer remains the leading
disease-related cause of death in
children and adolescents in North
America, with about 2,300 deaths each
year.
• Rhabdomyosarcoma accounts for
about 3 percent of childhood cancers. In
the U.S., about 350 children are
diagnosed with Rhabdomyosarcoma
each year.
Development Status: Early-stage of
development.
Inventors: Javed Khan et al. (NCI).
E:\FR\FM\08SEN1.SGM
08SEN1
]]>Agencies
[Federal Register Volume 73, Number 174 (Monday, September 8, 2008)]
[Notices]
[Pages 52053-52054]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-20778]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Simulations for Drug
Related Science Education
SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Institute on Drug Abuse (NIDA), the
National Institutes of Health (NIH) has submitted to the Office of
Management and Budget (OMB) a request for review and approval of the
information collection listed below. This proposed information
collection was previously published in the Federal Register on June 26,
2008, (Vol. 73 No. 124, page 36337) and allowed 60-days for public
comment. No public comments were received. The purpose of this notice
is to allow an additional 30 days for public comment. The National
Institutes of Health may not conduct or sponsor, and the respondent is
not required to respond to, an information collection that has been
extended, revised, or implemented on or after September 24, 2008,
unless it displays a currently valid OMB control number.
Proposed Collection: Title: Simulations for Drug Related Science
Education. Type of Information Collection Request: NEW. Need and Use of
Information Collection: This is a request for a one-time clearance to
evaluate an interactive multimedia module developed by ArchieMD. This
evaluation seeks to determine whether the multimedia module Archie MD:
The Science of Drugs (1) Increases students' knowledge in brain and
heart biology and the effects drugs have on the body (2) Increases
positive attitudes towards science education for high school students
(3) Reinforce or instill negative
[[Page 52054]]
attitudes towards substance abuse. In order to test the effectiveness
of the interactive multimedia module, data will be collected in the
form of pre and post test surveys from 10th and 11th grade high school
students utilizing the developed module. The findings will provide
valuable information regarding information pertaining to the use of
interactive multimedia educational modules in high school science
classrooms and their ability to increase knowledge and change attitudes
and perceptions.
Frequency of Response: 4. Affected Public: High school students
engaged with the ArchieMD: The Science of Drugs program. Type of
Respondent: Participants will include high school students enrolled in
the tenth and eleventh grade. Estimated Total Annual Number of
Respondents: 360. Estimated Number of Responses per Respondent: 4.
Average Burden Hours per Response: One high school period lasting 50
minutes. Estimated Total Annual Burden Hours Requested: 1199.95. There
are no Capital Costs to report. There are no Operating or Maintenance
Costs to report. The estimated annualized burden is summarized below.
----------------------------------------------------------------------------------------------------------------
Estimated
Number of Frequency of Average total burden
Type of respondents respondents response burden hours hours
per response requested
----------------------------------------------------------------------------------------------------------------
Participants--High School Students.............. 360 4 .8333 1199.95
---------------------------------------------------------------
Total....................................... 360 4 .8333 1199.95
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information shall have practical utility; (2) the
accuracy of the agency's estimate of the burden of the proposed
collection of information; (3) ways to enhance the quality, utility,
and clarity of the information to be collected; and (4) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30-days
of the date of this publication.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection
plans, please contact Dr. Cathrine Sasek, Coordinator, Science
Education Program, Office of Science Policy and Communications,
National Institute on Drug Abuse, 6001 Executive Blvd, Room 5237,
Bethesda, MD 20892, or call non-toll-free number (301) 443-6071; fax
(301) 443-6277; or by e-mail to csasek@nida.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60-days
of the date of this publication.
Dated: August 25, 2008.
Mary Affeldt,
Associate Director for Management, National Institute on Drug Abuse,
National Institutes of Health.
[FR Doc. E8-20778 Filed 9-5-08; 8:45 am]
BILLING CODE 4140-01-P
